Loading stock analysis…
Evidence Synthesis
Last synthesized: 20 Oct 2026, 09:29
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence velocity
Rate-of-change signals for this ticker unlock with Pro — or view flagship demos TCS / RELIANCE.
Evidence Synthesis
Omicron Pharmaceuticals (OLPCL) closed at 2.92 INR on October 19, 2026, with a daily volume of 91 shares.
The company's gross margin accelerated to 11.87%, up from . On a quarterly basis, the marginal operating leverage moved to -29.99%, a decline from -2.82%. Revenue growth year-over-year accelerated to .
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 11.87 % | -29.99 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | -29.99 % | -2.82 | ▼ |
| REVENUE_GROWTH_YOY | 16.4 % | — | - |
| PRICE_CHANGE_PERCENT | -0.68 % | — | - |
| DAILY_VOLUME | 91 shares | 3,110 | ▼ |
| CLOSE_PRICE | 2.92 INR | 2.94 | ▼ |
Cite this
Source: Samhati evidence synthesis for OLPCL (2026-10-20). Observation: Omicron Pharmaceuticals (OLPCL) closed at 2.92 INR on October 19, 2026, with a daily volume of 91 shares. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/olpcl
Filing step-changes